You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Pharma’s dwindling alliances
The pharmaceutical industry didn’t have many friends that stuck up for it when Democrats passed a historic drug pricing law in 2022. By the beginning of 2025, even many of the industry’s remaining allies will have left Congress, Rachel Cohrs Zhang reports.
Six of the industry’s closest friends on Capitol Hill that have served a collective 160 years in Congress have either already left or will likely leave this election cycle. Many have important positions on committees with jurisdiction over health care, and knowledge bases that will be difficult to replace
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect